Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 1 min ago
Peer-reviewedCC BY-NC-NDOpen forum infectious diseases

Weight Gain During Successful Tuberculosis Treatment Increases the Risk of Post-tuberculosis Metabolic Syndrome.

  • Argita D Salindri1,2
  • Teona Avaliani3
  • Mariam Gujabidze3
  • Leila Goginashvili3
  • Sergo Vashakidze3,4
  • Zaza Avaliani3,5
  • Sara C Auld6,7
  • Jeffrey M Collins8,9
  • Jason R Andrews2
  • Russell R Kempker7,8
  • Hardy Kornfeld10
  • Maia Kipiani3,4,11
1 more authors
  • Matthew J Magee7,8,9
11 affiliations
  1. 1Department of Population Health Sciences, Georgia State University School of Public Health, Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
  2. 2Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  3. 3National Center for Lung Health, Tbilisi, Georgia.
  4. 4The University of Georgia, Tbilisi, Georgia.
  5. 5European University, Tbilisi, Georgia.
  6. 6Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  7. 7Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
  8. 8Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  9. 9Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  10. 10Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
  11. 11David Tvildiani Medical University, Tbilisi, Georgia.
Read full textPDFDOICite

Abstract

Background

Little is known about the relationship between weight gain during treatment and the subsequent risk of cardiovascular and metabolic (cardiometabolic) diseases. We assessed the relationship between changes in body mass index (BMI) during tuberculosis (TB) treatment and prevalence of post-TB metabolic syndrome, a strong predictor of cardiometabolic diseases.Methods

We enrolled a prospective cohort of individuals successfully treated for TB disease in Tbilisi, Georgia, from 2019 to 2022. Eligible participants were HIV-negative individuals aged ≥16 years with newly diagnosed and laboratory-confirmed pulmonary TB. The primary exposure was relative change in BMI from treatment initiation to treatment completion, dichotomized at a ≥5% relative increase. Our primary study outcome was prevalence of post-TB metabolic syndrome (≥3 of the following: elevated blood pressure, elevated triglycerides, low high-density lipoprotein, elevated glycated hemoglobin [HbA1c], and abdominal obesity) at any study visit (including the end of treatment, 6 months post-TB treatment, and 12 months post-TB treatment). Multilevel models were used to estimate the effect of BMI change on post-TB metabolic syndrome.Results

Among 120 participants, the adjusted risk of having metabolic syndrome after TB treatment among those with a ≥5% relative increase in BMI was 2.1 times (95% CI, 1.1-4.0) the risk of those with a <5% relative increase in BMI during treatment. Additionally, the adjusted mean of post-TB HbA1c among those with a ≥5% relative increase in BMI was 0.4 (95% CI, 0.0-0.7) points higher compared with those with a <5% relative increase in BMI.Conclusions

Among individuals who were successfully treated, individuals who had a ≥5% increase in BMI during TB treatment had a significantly increased risk of metabolic syndrome and higher HbA1c levels up to 12 months after TB treatment.

Related

  1. Successful treatment of lamotrigine-induced Stevens-Johnson syndrome with upadacitinib.
    Amishi Taneja, Jacob Kingsley, Severine Z Cao +2
    JAAD case reportsPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  2. Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report.
    Hishan Tharmaseelan, Christian Peter Jaworek, Peter Borchmann +10
    Cancer chemotherapy and pharmacologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Conservative management of crowned dens syndrome and atlas posterior arch resection: Two successful experiences of individualized treatment.
    Yulin Liu, Xinye Li, Zhenyu Wang +3
    Experimental and therapeutic medicinePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  4. Polyendocrine metabolic ovarian syndrome: a new name to support better treatment.
    Ginevra Mills
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadiennePeer-reviewedCC BY-NC-NDFull textObstetrics, gynaecology & paediatricsEurope PMC
  5. Treatment-Resistant Psychosis in an Adolescent at Risk of Metabolic Syndrome: A Case Report.
    Michael Belkin, Jasmin Grewal
    CureusPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{salindri2026weight,
  title = {{Weight Gain During Successful Tuberculosis Treatment Increases the Risk of Post-tuberculosis Metabolic Syndrome.}},
  author = {Argita D Salindri and Teona Avaliani and Mariam Gujabidze and Leila Goginashvili and Sergo Vashakidze and Zaza Avaliani and Sara C Auld and Jeffrey M Collins and Jason R Andrews and Russell R Kempker and Hardy Kornfeld and Maia Kipiani and Matthew J Magee},
  journal = {Open forum infectious diseases},
  year = {2026},
  month = oct,
  doi = {10.1093/ofid/ofag620},
  url = {https://europepmc.org/article/MED/42921476},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Weight Gain During Successful Tuberculosis Treatment Increases the Risk of Post-tuberculosis Metabolic Syndrome.
AU  - Argita D Salindri
AU  - Teona Avaliani
AU  - Mariam Gujabidze
AU  - Leila Goginashvili
AU  - Sergo Vashakidze
AU  - Zaza Avaliani
AU  - Sara C Auld
AU  - Jeffrey M Collins
AU  - Jason R Andrews
AU  - Russell R Kempker
AU  - Hardy Kornfeld
AU  - Maia Kipiani
AU  - Matthew J Magee
PY  - 2026
DA  - 2026/10/01
JO  - Open forum infectious diseases
DO  - 10.1093/ofid/ofag620
UR  - https://europepmc.org/article/MED/42921476
AB  - Background  Little is known about the relationship between weight gain during treatment and the subsequent risk of cardiovascular and metabolic (cardiometabolic) diseases. We assessed the relationship between changes in body mass index (BMI) during tuberculosis (TB) treatment and prevalence of post-TB metabolic syndrome, a strong predictor of cardiometabolic diseases.Methods  We enrolled a prospective cohort of individuals successfully treated for TB disease in Tbilisi, Georgia, from 2019 to 2022. Eligible participants were HIV-negative individuals aged ≥16 years with newly diagnosed and laboratory-confirmed pulmonary TB. The primary exposure was relative change in BMI from treatment initiation to treatment completion, dichotomized at a ≥5% relative increase. Our primary study outcome was prevalence of post-TB metabolic syndrome (≥3 of the following: elevated blood pressure, elevated triglycerides, low high-density lipoprotein, elevated glycated hemoglobin [HbA1c], and abdominal obesity) at any study visit (including the end of treatment, 6 months post-TB treatment, and 12 months post-TB treatment). Multilevel models were used to estimate the effect of BMI change on post-TB metabolic syndrome.Results  Among 120 participants, the adjusted risk of having metabolic syndrome after TB treatment among those with a ≥5% relative increase in BMI was 2.1 times (95% CI, 1.1-4.0) the risk of those with a <5% relative increase in BMI during treatment. Additionally, the adjusted mean of post-TB HbA1c among those with a ≥5% relative increase in BMI was 0.4 (95% CI, 0.0-0.7) points higher compared with those with a <5% relative increase in BMI.Conclusions  Among individuals who were successfully treated, individuals who had a ≥5% increase in BMI during TB treatment had a significantly increased risk of metabolic syndrome and higher HbA1c levels up to 12 months after TB treatment.
SN  - 2328-8957
ER  -